T3D Therapeutics, Inc. Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer's Patients RESEARCH TRIANGLE PARK, N.C., June 22, 2015 (GLOBE NEWSWIRE) -- via PRWEB - T3D Therapeutics, Inc., a Research Triangle Park, NC-based developer of Alzheimer's disease therapies, announced today that...

T3D Therapeutics, Inc. Awarded SBIR Phase 2 Grant From The National Institute On Aging For Alzheimer's Disease Drug Testing RESEARCH TRIANGLE PARK, N.C., March 24, 2015 (GLOBE NEWSWIRE) -- via PRWEB - T3D Therapeutics, Inc., a Research Triangle Park, NC-based developer of Alzheimer's disease therapies announced today that...